nach oben

Erschienen in:

01.07.2014 | Original Paper

TGF-β1-induced expression of Id-1 is associated with tumor progression in gastric cancer

verfasst von: Huiying Ma, Ye Wei, Yongmei Leng, Shichao Li, Lingling Gao, Heng Hu, Long Chen, Fei Wang, Honglei Xiao, Chouwen Zhu, Chunmin Liang

Erschienen in: Medical Oncology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Transforming growth factor β1 (TGF-β1) and inhibitor of differentiation/DNA-binding 1 (Id-1) have been shown to be associated with aggressive metastatic behavior of cancer cells in many malignant tumors. However, their role in gastric cancer (GC) has not been established. In this study, we investigated the relationship between expression of Id-1 and TGF-β1 in GC as well as their association with GC progression. The immunohistochemical analysis of 71 human GC samples indicated that both Id-1 and TGF-β1 were markedly upregulated in tumor tissue compared with the adjacent tissue; in addition, a significant positive correlation was found between the expression levels of Id-1 and TGF-β1 by Pearson’s correlation analysis. Furthermore, the investigation of the association of Id-1 and TGF-β1 with patient clinical characteristics revealed that Id-1 expression was significantly correlated with tumor differentiation, while TGF-β1 was associated with lymph node metastasis. The results were validated in vitro by using a GC cell line, AGS. The expression of Id-1 was upregulated at 24 and 48 h after the treatment with TGF-β1, whereas it did not affect the proliferation of cells. TGF-β1 also influenced the expression of N-cadherin and β-catenin. Our results suggested that Id-1 and TGF-β1 played important roles in the progression of GC, in which Id-1 might act as a downstream mediator of TGF-β1 signaling through a regulatory mechanism involving N-cadherin and β-catenin. The TGF-β1/Id-1 axis might serve as a future therapeutic target for GC.

Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374(9688):477–90.PubMedCrossRef

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef

Oue N, Aung PP, Mitani Y, Kuniyasu H, Nakayama H, Yasui W. Genes involved in invasion and metastasis of gastric cancer identified by array-based hybridization and serial analysis of gene expression. Oncology. 2005;69(Suppl. 1):17–22.PubMedCrossRef

Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer. 2005;8(2):86–94.PubMedCrossRef

Perk J, Iavarone A, Benezra R. Id family of helix–loop–helix proteins in cancer. Nat Rev Cancer. 2005;5(8):603–14.PubMedCrossRef

Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O’Reilly R, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 1999;401(6754):670–7.PubMedCrossRef

Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, et al. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell. 2002;2(6):473–83.PubMedCrossRef

Schindl M, Schoppmann SF, Ströbel T, Heinzl H, Leisser C, Horvat R, et al. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res. 2003;9(2):779–85.PubMed

Kebebew E, Peng M, Treseler PA, Clark OH, Duh Q-Y, Ginzinger D, et al. Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells. J Clin Endocrinol Metab. 2004;89(12):6105–11.PubMedCrossRef

10.

Fong S, Itahana Y, Sumida T, Singh J, Coppe J-P, Liu Y, et al. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci. 2003;100(23):13543–8.PubMedCentralPubMedCrossRef

11.

Yuen H, Chan Y, Chan K, Chu Y, Wong ML, Law SY, et al. Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer. 2007;97(10):1409–15.PubMedCentralPubMedCrossRef

12.

Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res. 2013;73(5):1559–69.PubMedCentralPubMedCrossRef

13.

Sumida T, Murase R, Onishi-Ishikawa A, McAllister SD, Hamakawa H, Desprez P-Y. Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells. BMC Cancer. 2013;13(1):141.PubMedCentralPubMedCrossRef

14.

Oien KA, Vass JK, Downie I, Fullarton G, Keith WN. Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. Oncogene. 2003;22(27):4287–300.PubMedCrossRef

15.

Wang Q, Tsao SW, Fu S, Xue W, Meng X, Feng H, et al. Overexpression of Id-1 in gastric adenocarcinoma: implication for a novel diagnostic marker. Anticancer Res. 2004;24(2B):881–6.PubMed

16.

Iwatsuki M, Fukagawa T, Mimori K, Nakanishi H, Ito S, Ishii H, et al. Bone marrow and peripheral blood expression of ID1 in human gastric carcinoma patients is a bona fide indicator of lymph node and peritoneal metastasis. Br J Cancer. 2009;100(12):1937–42.PubMedCentralPubMedCrossRef

17.

Han S, Guo C, Hong L, Liu J, Liu C, Wang J, et al. Expression and significance of Id1 helix–loop–helix protein overexpression in gastric cancer. Cancer Lett. 2004;216(1):63–71.PubMedCrossRef

18.

Jang TJ, Jung KH, Choi EA. Id-1 gene downregulation by sulindac sulfide and its upregulation during tumor development in gastric cancer. Int J Cancer. 2006;118(6):1356–63.PubMedCrossRef

19.

Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990;6(1):597–641.PubMedCrossRef

20.

Yang L, Pang Y, Moses HL. TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31(6):220–7.PubMedCentralPubMedCrossRef

21.

Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 2000;103(2):295–309.PubMedCrossRef

22.

Lu S-L, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M, et al. Overexpression of transforming growth factor β1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 2004;64(13):4405–10.PubMedCrossRef

23.

Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, et al. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci. 2000;97(6):2626–31.PubMedCentralPubMedCrossRef

24.

Benckert C, Jonas S, Cramer T, von Marschall Z, Schäfer G, Peters M, et al. Transforming growth factor β1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003;63(5):1083–92.PubMed

25.

Sun L, Diamond ME, Ottaviano AJ, Joseph MJ, Ananthanarayan V, Munshi HG. Transforming growth factor-β1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through Snail Expression. Mol Cancer Res. 2008;6(1):10–20.PubMedCrossRef

26.

Gomes LR, Terra LF, Wailemann RA, Labriola L, Sogayar MC. TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer. 2012;12(1):26.PubMedCentralPubMedCrossRef

27.

Ling M, Wang X, Tsao S, Wong Y. Down-regulation of Id-1 expression is associated with TGFβ1-induced growth arrest in prostate epithelial cells. Biochim Biophys Acta (BBA) Gen Subj. 2002;1570(3):145–52.CrossRef

28.

Di K, Wong YC, Wang X. Id-1 promotes TGF-β1-induced cell motility through HSP27 activation and disassembly of adherens junction in prostate epithelial cells. Exp Cell Res. 2007;313(19):3983–99.PubMedCrossRef

29.

Di K, Ling MT, Tsao SW, Wong YC, Wang X. Id-1 modulates senescence and TGF-β1 sensitivity in prostate epithelial cells. Biol Cell. 2006;98(9):523–33.PubMedCrossRef

30.

Goumans M-J, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J. 2002;21(7):1743–53.PubMedCentralPubMedCrossRef

31.

Padua D, Zhang XH-F, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66–77.PubMedCentralPubMedCrossRef

32.

Strong N, Millena AC, Walker L, Chaudhary J, Khan SA. Inhibitor of differentiation 1 (Id1) and Id3 proteins play different roles in TGFβ effects on cell proliferation and migration in prostate cancer cells. Prostate. 2012;73(6):624–33.PubMedCentralPubMedCrossRef

33.

Huber MA, Kraut N, Beug H. Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548–58.PubMedCrossRef

34.

Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679–95.PubMedCrossRef

35.

Gomis RR, Alarcón C, Nadal C, Van Poznak C, Massagué J. C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell. 2006;10(3):203–14.PubMedCrossRef

36.

Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Over expression of ID-1 in prostate cancer. J Urol. 2002;167(6):2598–602.PubMedCrossRef

37.

Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, et al. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer. 1997;76(2):244–50.PubMedCentralPubMedCrossRef

38.

Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer. 1998;77(9):1492–4.PubMedCentralPubMedCrossRef

39.

Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, et al. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol. 1999;17(2):607–14.PubMed

40.

Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992;52(24):6949–52.PubMed

41.

Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer. 2007;7:156.PubMedCentralPubMedCrossRef

42.

Meteoglu I, Meydan N, Erkus M. Id-1: regulator of EGFR and VEGF and potential target for colorectal cancer therapy. J Exp Clin Cancer Res. 2008;27:69.PubMedCentralPubMedCrossRef

43.

Kim MS, Park TI, Lee YM, Jo YM, Kim S. Expression of Id-1 and VEGF in non-small cell lung cancer. Int J Clin Exp Pathol. 2013;6(10):2102–11.PubMedCentralPubMed

44.

Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18(6):655–68.PubMedCrossRef

45.

Ding Y, Wang G, Ling MT, Wong YC, Li X, Na Y, et al. Significance of Id-1 up-regulation and its association with EGFR in bladder cancer cell invasion. Int J Oncol. 2006;28(4):847–54.PubMed

46.

Yang S, Guo LJ, Tang XF, Tan K, Gong RG, Li A, et al. The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis. Int J Oral Maxillofac Surg. 2010;39(1):29–35.PubMedCrossRef

47.

Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell. 2003;11(4):915–26.PubMedCrossRef

48.

Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.PubMedCrossRef

49.

Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–72.PubMedCrossRef

50.

Zhang X, Ling MT, Wang Q, Lau CK, Leung SC, Lee TK, et al. Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J Biol Chem. 2007;282(46):33284–94.PubMedCrossRef

51.

Li B, Tsao SW, Li YY, Wang X, Ling MT, Wong YC, et al. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int J Cancer. 2009;125(11):2576–85.PubMedCrossRef

52.

Stankic M, Pavlovic S, Chin Y, Brogi E, Padua D, Norton L, et al. TGF-beta-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep. 2013;5(5):1228–42.PubMedCrossRef

Titel: TGF-β1-induced expression of Id-1 is associated with tumor progression in gastric cancer
verfasst von: Huiying Ma
Ye Wei
Yongmei Leng
Shichao Li
Lingling Gao
Heng Hu
Long Chen
Fei Wang
Honglei Xiao
Chouwen Zhu
Chunmin Liang
Publikationsdatum: 01.07.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 7/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0019-3

Springer Medizin

TGF-β1-induced expression of Id-1 is associated with tumor progression in gastric cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2014

Investigation of the association of hRRM1 and p53R2 gene polymorphisms in head and neck squamous cell carcinomas

Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer

Decreased ITIH5 expression is associated with poor prognosis in primary gastric cancer

Low expression of novel lncRNA RP11-462C24.1 suggests a biomarker of poor prognosis in colorectal cancer

Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer

Overexpression of NUAK1 is associated with disease-free survival and overall survival in patients with gastric cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie